We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

2 days ago
Regulatory

Bay­er’s $240M up­front for Blue­Rock ac­qui­si­tion puts them in the high rollers club for pre­clin­i­cal biotech buy­outs

2 weeks ago
Deals
Discovery

No­var­tis' $18.5B in M&A un­der Vas Narasimhan says a lot about their care­ful — but op­por­tunis­tic — deal strat­e­gy

4 weeks ago
Deals

What makes Hal Bar­ron tick? Look at the peo­ple he’s team­ing up with at GSK

4 weeks ago
Bioregnum
People

As Take­da ab­sorbs Shire’s R&D ops, the fo­cus is on re­plac­ing a cen­tral­ized com­mand mod­el with a ‘light touch’ in a re­struc­tured glob­al or­ga­ni­za­tion

5 weeks ago
Deals
R&D

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

Last month
Deals

The top 15 mega-deals in bio­phar­ma: Ab­b­Vie and Bris­tol-My­ers ac­qui­si­tions stir fresh de­bate over what's too big to buy

Last month
Deals

Gene ther­a­py R&D deals turn red hot as Big Phar­ma steps up to play

2 months ago
Cell/Gene Tx
Deals

Bio­phar­ma BD teams are speed­ing in­to the fast lane — cash in hand — as deal­mak­ing con­tin­ues to heat up in Q1 of­fen­sive

3 months ago
Pharma

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

3 months ago
People

The BC­MA fren­zy: Track­ing the 37 drugs around the world rac­ing to over­take blue­bird bio and Cel­gene

3 months ago
R&D

Top 5 Chi­nese play­ers: What does Ever­est's land­mark deal with Im­munomedics say about the flur­ry of in-li­cens­ing to Chi­na?

3 months ago
China

Go­ing gang­busters: The top 20 biotech plat­form deals by up­front cash

4 months ago
Pharma

An­oth­er play­er in the gene ther­a­py field is gun­ning for the Duchenne MD crown — and here’s what they're bet­ting on

4 months ago
Bioregnum
Cell/Gene Tx

The top 20 pre­clin­i­cal biotech deals ranked by cash up­front re­veals 3 big play­ers — and some ma­jor league stinkers

4 months ago
Deals
Discovery

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

4 months ago
Pharma

The top 10 Alzheimer's deals tell us a lot about a big change of di­rec­tion for a dis­as­ter-prone field

4 months ago
Pharma
R&D

Team build­ing. Pipeline re­vamp. For­ward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

5 months ago
Pharma

Af­ter a slate of small, tack-on ac­qui­si­tions, is Mer­ck ready to pull the trig­ger on a big M&A deal?

5 months ago
Pharma

By the num­bers: Top M&A deals, VC in­vest­ments and pacts point to a grow­ing hunger for gene ther­a­py deals

5 months ago
Cell/Gene Tx
Pharma

The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

6 months ago
Pharma

The high rollers: The top 20 block­buster bio­phar­ma deals of the past decade

6 months ago
Pharma

Top 20 biotech deals: 2019 deal­mak­ing gets off to a roar­ing start, build­ing on a record amount for '18

6 months ago
Pharma

As­traZeneca CEO So­ri­ot is over­see­ing a top ex­ec team over­haul in move to in­te­grate Med­Im­mune in a sweep­ing re­struc­tur­ing

6 months ago
People
123 Next page Last page